• Indexing List

IP International Journal of Medical Paediatrics and Oncology


Eltrombopag in Children


Full Text PDF Share on Facebook Share on Twitter


Author Details: Priti S. Mehta

Volume : 1

Issue : 1

Online ISSN : 2581-4702

Print ISSN : 2581-4699

Article First Page : 20

Article End Page : 23


Abstract

Immune (idiopathic) thrombocytopenic purpura (ITP), a disease of low platelet count affects as many as 5 in 100,000 children each year.1 Being a self-remitting illness patients usually don’t need aggressive treatment. However  up to 30 percent of children are diagnosed with chronic ITP (cITP) experiencing persistent disease at 1 year from beginning of symptomatology.2,3,4 Patients with paediatric cITP are at a high risk of severe bleeding due to low platelet counts. Line of treatment for cITP in children include rituximab, high dose dexamethasone therapy, dapsone, multiple single agents, splenectomy and last but not the least thrombopoeitin receptor agonists like eltrombopag which is approved by U.S. FDA for use in children. Eltrombopag being an oral drug compared to other modalities has shown very promising results in paediatric patients with cITP, has attained a consistent platelet response for 6 of 8 weeks compared to placebo (39.7% vs 3.4% respectively, p < 0.001).

Keywords: Eltrombopag, Chronic immune thrombocytopenic purpura, Thrombopoietin –receptor agonist
Modalities of Treating Chronic ITP in Children5,6,7

1.        Rituximab

2.        High dose dexamethasone therapy

3.        Dapsone

4.        Numerous agents such as azathioprine, danazol, interferon, mycophenolate mofetil,,cyclosporine, antiCD52 monoclonal antibody

5.        Splenectomy

6.        Thrombopoeitin receptor agonists